Conflicting data have emerged regarding the role of complement activation in the pathophysiology of cerebral ischemia. On the basis of considerable evidence implicating inflammatory mediators in the progression of neonatal brain injury, we evaluated the contribution of complement activation to cerebral hypoxic-ischemic (HI) injury in the neonatal rat. To elicit unilateral forebrain HI injury, 7-d-old rats underwent right carotid ligation followed by 1.5-2 hr of exposure to 8% oxygen. Using immunoprecipitation and Western blot assays, we determined that HI induces local complement cascade activation as early as 8 hr post-HI; there was an eightfold increase in the activation fragment inactivated C3b at 16 hr. With immunofluorescence assays and confocal microscopy, both C3 and C9 were localized to injured neurons 16 and 24 hr post-HI. To investigate the contribution of systemic complement to brain injury, we administered the complementdepleting agent cobra venom factor (CVF) 24 hr before HI lesioning and evaluated both acute HI-induced complement deposition and the extent of resulting tissue injury 5 d after lesioning. CVF depleted both systemic and brain C3 by the time of surgery and reduced infarct size. Analysis of lesioned, CVF-treated animals demonstrated minimal neuronal C3 deposition but no reduction in C9 deposition. C3-immunoreactive microglia were identified in injured areas. These results indicate that complement activation contributes to HI injury in neonatal rat brain, systemic administration of CVF does not eliminate complement deposition within injured brain, and microglia may represent an important local source of C3 after acute brain injury.
Introduction
Substantial evidence implicates complement activation in the pathogenesis of diverse acute and chronic CNS disorders (Morgan et al., 1997; Singhrao et al., 1999; D'Ambrosio et al., 2001) . The complement cascade is the effector arm of the innate and humoral immune systems. Complement activation refers to the process of complement cascade initiation and execution, which results in the production of inflammatory mediators (C3a, C5a), the opsonization of cells with components [C3b, inactivated C3b (iC3b)] for recognition and phagocytosis by macrophages, and the formation of lethal membrane attack complexes (MAC) (C5b-9) on target membranes. The term "deposition" describes the fixation of complement to cell membranes resulting from local complement activation. Multiple activators of complement are present in injured tissue, including phosphatidylserine on apoptotic cells (Mevorach et al., 1998) , mitochondria or naked DNA released from necrotic cells (Gewurz et al., 1993) , and extracellular matrix molecules (Hindmarsh and Marks, 1998) .
A role for complement in ischemia-reperfusion injury was first established by Hill and Ward (1971) ; they pretreated animals with the active C3b homolog cobra venom factor (CVF) to deplete systemic complement and reported a marked reduction in myocardial ischemic damage and neutrophil infiltration. Subsequently, CVF-induced complement depletion has been used to examine the role of complement activation in many models of ischemia-reperfusion injury. In models of CNS ischemic injury, conflicting findings have emerged. CVF improved cerebral blood flow and behavioral outcome after transient forebrain ischemia (Vasthare et al., 1998) but did not confer neuroprotection in a rabbit thromboembolic stroke model (Lew et al., 1999) . To date, the strongest evidence implicating complement activation in the pathogenesis of ischemia-reperfusion brain injury used an alternative approach to inhibit complement activation. Huang et al. (1999) found that treatment with a fusion protein consisting of soluble complement receptor 1 and Sialyl Lewis x reduced neutrophil accumulation and cerebral infarct volumes in a mouse model of transient forebrain ischemia.
There is growing recognition that inflammation contributes to the pathogenesis of neonatal brain injury (Barks and Silverstein, 2002) . Clinical data linking complement activation with neonatal brain injury include evidence that C3 is depleted after neonatal asphyxia (Grether et al., 1999) , and that serum C3a and C5a increase after fetal acidosis (Sonntag et al., 1998) . Two previous studies have evaluated the role of complement in neonatal brain injury models; CVF treatment did not reduce injury in a neonatal rodent hypoxic-ischemic (HI) model (Lassiter et al., 2001 ), but administration of C9 exacerbated injury in a similar model (Imm et al., 2002) . These discrepant findings prompted us to reexamine whether complement activation contributes to neo-natal brain damage in a well characterized model of HI brain injury in 7-d-old [postnatal day (P) 7] rats. We evaluated the time course and neuroanatomical localization of HI-induced complement activation and used CVF to investigate the sources of complement in acutely injured brain and the impact of systemic complement depletion on the extent of tissue damage. We demonstrate that complement is activated acutely in HI brain and that complement depletion reduces HI-induced complement activation and injury.
Materials and Methods
Antibodies and reagents. Primary antibodies and reagents used for immunohistochemistry and fluorescence included mouse anti-neuronalspecific nuclear protein (NeuN) (neurons; Chemicon, Temecula, CA), FITC-or biotin-conjugated Isolectin B 4 (endothelium and microglia; Sigma, St. Louis, MO), goat anti-rat C3 (ICN Pharmaceuticals, Aurora, OH), rabbit anti-rat C9 (generously provided by B. P. Morgan, University of Wales College of Medicine, Cardiff, UK), rabbit anti-rat activated caspase 3 (Cell Signaling Technology, Beverly, MA), and 4Ј,6Ј-diamidino-2-phenylindole (DAPI) (Molecular Probes, Eugene, OR). Secondary antibodies included biotinylated horse anti-mouse IgG, horse anti-goat IgG, goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA), CY-2-conjugated donkey anti-mouse IgG, CY-3 donkey anti-goat IgG, and CY-5 donkey anti-rabbit IgG (preabsorbed for rat serum proteins; Jackson ImmunoResearch, West Grove, PA).
Animal protocols. To elicit HI injury, unsexed P7 Sprague Dawley rats (10 -15 gm) underwent right carotid ligation under continuous anesthesia with isofluorane as described previously (Cowell et al., 2002) . In brief, after recovery in a thermoregulated incubator (1 hr; 37°C), animals were placed in warmed chambers (partly submerged in a 36.5°C water bath) and exposed to 8% O 2 /92% N 2 for 1.5 or 2 hr. After hypoxia, animals recovered in a warm incubator (37°C) for 30 min and were returned to the mother. In this model, the duration of hypoxia influences the severity of tissue injury, and the threshold duration of hypoxia to elicit reproducible ipsilateral forebrain injury is between 1 and 1.5 hr. In the first set of experiments (evaluation of the HI-induced complement activation and deposition in brain), we used a lesioning protocol, which elicits severe tissue damage in the majority of animals (2 hr HI). For the experiments evaluating potential injury-modifying interventions, we used a lesioning protocol that would enable us to readily discern either neuroprotection or exacerbation of injury (1.5 hr HI).
To generate positive control brain samples for complement assays, the proinflammatory agent Zymosan A (particulate component of yeast cell wall; Sigma) was stereotaxically infused over Ͻ1 min, as a bolus injection, into the right cortex of isofluorane-anesthetized P7 rats (0.5 l; 10 mg/ml in sterile PBS; 1.5 mm posterior to Bregma; 2 mm lateral; 1 mm deep). C3 cleavage (see Results) was detected 8 -48 hr after injection. On the basis of the review of cresyl violet-stained sections and caspase 3 immunohistochemistry, it appeared that Zymosan infusion did not induce cell death, remote from injection site-related trauma. Although C3 immunostaining increased diffusely in the injected hemisphere, we found no cellular deposition of C3 or C9 (data not shown).
To investigate the influence of systemic complement depletion before HI lesioning, CVF (originally from cobra Naja naja kaouthia; Advanced Research Technologies, San Diego, CA) was administered by intraperitoneal injection. To assess the effects of CVF on serum and brain C3 at this age, unlesioned animals received injections of 0.1 M PBS or CVF (500 g/kg in 0.1 M PBS) on P6 and were killed on P7, P8, or P12 (n ϭ 6 per group). To determine the influence of CVF administration on HIinduced C3 and C9 accumulation and deposition and tissue injury, animals were injected with PBS or CVF on P6, lesioned 24 hr later on P7, and killed on P8 (for Western blot and immunohistochemistry; n ϭ 13 per group) or P12 (for histopathology; n ϭ 16 -17 per group). In the neuroprotection experiment, we estimated the group sample size required to identify a 20% difference in outcome, on the basis of results from previous studies in this model (␣ ϭ 0.05; ␤ ϭ 0.8; n ϭ 15 per group; Instat; Graphpad, San Diego, CA). All animal use protocols were approved by The University of Michigan Committee on Use and Care of Animals.
Tissue collection. To obtain tissue homogenates for Western blot analysis, animals were deeply anesthetized with an overdose of chloral hydrate (300 mg/kg) at 4, 8, 16, 24, or 72 hr after HI (n ϭ 3 per group) and perfused intracardially with ice-cold saline (to clear blood-borne complement). Brains were removed, divided into left and right hemispheres, and homogenized in PBS on ice (20 sec; maximum speed; Tissue Tearor; Biospec Products, Bartlesville, OK). Homogenates were centrifuged (13,000 rpm; 30 min), and supernatants were stored at Ϫ70°C. Protein content of the samples was determined using the D c protein assay kit (Bio-Rad, Hercules, CA) with BSA as a standard.
To obtain brain samples for immunohistochemistry and immunofluorescence assays, animals were anesthetized with chloral hydrate and perfused with PBS (10 ml) and 4% paraformaldehyde in PBS (10 ml) 8, 16, 24, or 72 hr after HI (n ϭ 3-4 per group). To determine the effects of CVF on brain C3 content, tissue was collected from animals 24 -48 hr after CVF or PBS injection. Brains were removed, postfixed overnight in 4% paraformaldehyde (in PBS) at 4°C, cryoprotected in graded sucrose solutions, embedded in Tissue-Tek OCT (VWR Scientific, Batavia, IL), frozen, and stored at Ϫ70°C (Ivacko et al., 1996) . Coronal sections through the striatum and hippocampus were collected on gelatin-subbed slides. Slides were dried overnight and either used immediately or stored at Ϫ70°C.
For analysis of serum complement content and hemolytic activity, blood (100 -400 l) was obtained from anesthetized animals immediately before perfusions by intracardiac puncture (22 gauge needle); samples were incubated at 37°C (30 min), placed on ice (30 min), and centrifuged at 2500 rpm at 4°C (10 min). The serum was collected and frozen at Ϫ70°C.
Immunoprecipitation and Western blot analysis. For analysis of serum C3, samples were diluted in PBS and loading buffer, boiled (100°C; 10 min), and loaded (5 g per lane) on a 10% acrylamide-SDS gel. Proteins were transferred to a Protran nitrocellulose membrane (Schleicher & Schuell, Keene, NH), and membranes were blocked in 5% fish skin gelatin in Tris-buffered saline (TBS; 0.15 M NaCl, 0.02 M Tris, pH 7.6) with 0.1% Tween 20 (Tw) overnight at 4°C. The goat anti-rat C3 antibody was applied to the membrane for 1.5 hr at room temperature (3% gelatin/ 0.02% Tw/TBS). The membrane was washed (0.5% Tw/TBS), incubated with peroxidase-labeled donkey anti-rabbit IgG (3% gelatin/0.02% Tw/ TBS), and washed again. The membrane was incubated with a chemiluminescent substrate (Pierce, Rockford, IL) and exposed to Kodak Biomax film (Kodak, Rochester, NY).
Although preliminary immunohistochemistry experiments revealed substantial C3 deposition in HI tissue, little C3 was detected in preliminary Western blot assays of brain tissue (100 g); thus, an immunoprecipitation protocol was developed. All incubations were performed at 4°C on a rotator. Samples (100 g) were added to 475 l of radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1% Triton X-100, 0.5% Na deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) and incubated with 1 g of goat anti-C3 antibody (2 hr). Protein G beads (40 l; 1:1 v/v in RIPA; Sigma) were added to the lysate-antibody preparation for 1 hr and then spun down (13,000 rpm; 5 min; 4°C) and washed three times with cold RIPA (high NaCl; 0.5 M) and once with RIPA (low NaCl; 0.15 M). The wash buffer was removed, and 25 l of 2ϫ loading buffer was added. Samples were briefly vortexed and then boiled (10 min; 100°C). The beads were spun down (5 min; 1000 rpm; room temperature), and the supernatant was loaded onto a 7.5 or 10% polyacrylamide gel for electrophoresis. Proteins were transferred to a nitrocellulose membrane, and C3 was detected as for serum (see above). Distinct bands were detected at 120 (␣C3), 70 (iC3b 1 ), 65 (␤C3), and 43 kDa (iC3b 2 ) (SawantMane et al., 1996) in both serum and brain samples. Negative controls for immunoprecipitation included both zymosan-injected brain homogenates incubated with nonspecific goat IgG (instead of the C3 antibody) and samples in which no tissue was added to the immunoprecipitation reaction (C3 antibody alone). Ponceau S (Sigma) was used to stain membranes after transfer to verify the equal loading of protein or C3 antibody in each lane.
Western blots were performed to measure brain content of C9; tissue homogenate supernatants (1 g of protein) were electrophoresed on a 7.5% polyacrylamide gel and processed as described above with the rab-bit anti-rat C9 and goat-anti rabbit IgG antibodies. A single band was detected at 70 kDa; note that under the denaturing and reducing conditions of the Western blot procedure, sources of C9 could have included free C9, soluble C5b-9, and membrane-bound MAC.
For quantitation of C3 and C9, the optical density (OD) of each band (arbitrary OD units; counts per square millimeter) was measured using the Molecular Analyst Imaging System (Bio-Rad). Values were expressed as fold increase in OD (right hemisphere/left hemisphere Ϫ 1), percentage of normal (compared on same film), or as arbitrary OD units. Several exposures of each film were taken to assure that the bands used for quantitation were not saturated (overexposed).
Immunohistochemistry and light microscopy. Immunohistochemistry and microscopy protocols have been reported previously (Cowell and Silverstein, 2003) . In brief, antibodies were diluted in PBS with 5% normal serum (same species as the host of the secondary antibody) and 0.3% Triton X-100. Sections were washed, blocked in 10% serum, and incubated with the primary antibody overnight at 4°C. Sections were washed, incubated with a biotinylated secondary antibody, rinsed with 0.3% H 2 O 2 in methanol, and washed before incubation with the avidin-biotin conjugate (Vectastain ABC Elite kit; Vector Laboratories). Immunoreactivity was visualized with diaminobenzidine as the chromogen (Research Genetics, Huntsville, AL). Sections were either counterstained briefly with cresyl violet or directly dehydrated and coverslipped with Permount. For negative controls, primary antibodies were replaced with an equal concentration of species-matched nonspecific IgG. Light microscopy was used to evaluate the extent of neuronal injury and complement deposition. Representative images were captured using a SPOT camera attached to a Nikon (Tokyo, Japan) Microphot-SA with 4ϫ, 10ϫ, 20ϫ, and 40ϫ objectives, and images were directly imported into Adobe Photoshop 5.5 (Adobe Systems, San Jose, CA) for the adjustment of brightness, contrast, and sharpness.
Immunofluorescence and confocal microscopy. After incubation with the primary antibodies (overnight at 4°C), sections were washed, incubated with the appropriate secondary antibodies (2 hr; room temperature), washed, and coverslipped with aqueous antifade media (Molecular Probes). Immunofluorescence was visualized in triple-channel mode on a Nikon Diaphot 200 microscope equipped with a Noran confocal laserscanning imaging system (Noran Instruments, Middleton, WI) and Silicon Graphics (Mountain View, CA) Indy workstation. Data were collected from each channel sequentially, and barrier filters minimized channel leak-through (500/25 bandpass barrier filter in the FITC/CY2 range; 605/55 bandpass barrier filter in the Rhodamine/CY3 range). The images from two or three channels were merged, and the brightness and contrast were adjusted with Adobe Photoshop 5.5 (Adobe Systems).
Hemolytic assay. To confirm complement depletion in CVF-treated animals, the total serum hemolytic activity of animals injected with PBS (n ϭ 4) or CVF (n ϭ 5) was determined using a CH 50 hemolytic assay (Kabat and Mayer, 1961) . Animals were injected on P6, and serum was isolated on P7 from 0.1-0.4 ml of blood from intracardiac aspiration before perfusion. Serial dilutions of serum (1:5, 1:10, 1:15, 1:20) were incubated with sensitized sheep erythrocytes (Advanced Research Technologies) for 30 min, the reaction was stopped with cold PBS, and the absorbance of the supernatant was read at 415 nm in triplicate. For the controls, the erythrocytes were incubated with water (100% lysis) or PBS alone (0% lysis; background). The CH 50 value represents the reciprocal of the dilution required to lyse 50% of the erythrocytes.
Histopathology. Five days after surgery (P12), animals (injected with PBS or CVF on P6; n ϭ 16 -17 per group) were decapitated, and brains were removed, frozen on dry ice, and sectioned on a cryostat (20 m) from anterior striatum to posterior hippocampus. Every fourth section was mounted on gelatin-subbed slides; every fourth collected section was scanned and imported into NIH Image 1 Statistical analysis. Means and SEMs were determined for each data set. For analysis of complement-related assays, the Kruskal-Wallis test was used to evaluate group differences. A two-way ANOVA (factoring treatment and region) was used to determine the effect of CVF treatment on lesion volume. Post hoc analyses were applied to identify differences between specific data points. Statistical significance was set at p Ͻ 0.05.
Results
We incorporated two experimental methods to document complement activation in hypoxic-ischemic neonatal brain: the identification of inactivated C3b (iC3b) and C9 in injured tissue by Western blot and the localization of complement components C3 and C9 to the membranes of injured cells with immunohistochemistry and immunofluorescence. All animals were perfused with saline before brain removal and processing to minimize contamination of the samples with blood-derived complement components.
C3 is an essential component of the C3 convertase, the enzyme complex responsible for complement cascade progression and amplification. With immunoprecipitation and Western blot analysis, we identified the two chains of native C3 (␣: 120 kDa and ␤: 65 kDa) and two C3 activation fragments (iC3b; 70 kDa and 43 kDa) in HI brain (Fig. 1 A) . The heavy chain of goat IgG used to capture C3 was detected in all lanes (50 kDa); this was the only band detectable in negative control lanes (lane 1, C3 antibody alone; lane 2, positive control tissue plus nonspecific goat IgG). Little ␣C3 or ␤C3 was detectable in normal brain ( Fig. 1 A, lane 3). As a positive control for complement activation in brain parenchyma, the complement activator Zymosan A (10 g/l) was injected into the right cortex. Zymosan stimulated C3 production (increases in ␣C3 and ␤C3) as well as complement activation (increase in iC3b; both 70 and 43 kDa fragments) ( Fig. 1 A,  lane 4) .
In a sample from the contralateral hemisphere 24 hr after 2 hr HI (Fig. 1 A; lane 5, HI-L), the 70 kDa iC3b band was evident but the 43 kDa iC3b was faint, whereas in the right (ipsilateral) hemisphere, both iC3b bands were increased (Fig. 1 A; lane 6 HI-R). The intensity of the 43 kDa iC3b band was similar to that in the zymosan-injected tissue. The 43 kDa band was selected for quantitative analysis, because it was the strongest band in zymosanexposed serum (positive control; data not shown). Figure 1 B summarizes results of quantitative analysis of the 43 kDa iC3b band in samples obtained from animals 4, 8, 16, 24 , and 72 hr after HI (2 hr HI). iC3b accumulation was highest at 16 hr after HI (Fig. 1 B) (n ϭ 3 per group; p ϭ 0.017; Kruskal-Wallis test).
Tissue C9 content was analyzed by Western blot in the same samples. Figure 1C shows a C9 Western blot of normal and HI brain; C9 was detectable in normal P8 brain, and increases were evident 24 hr after HI in the right (Fig. 1C, R) hemispheres when compared with normal P8 (Fig. 1C, N ) and left hemispheres (Fig.  1C, L) . C9 content in the right hemisphere increased threefold over normal control levels between 8 and 24 hr after HI (Fig. 1 D) (n ϭ 3 per group; p ϭ 0.02; Kruskal-Wallis test). Slight increases in C9, as well as ␣C3 and iC3b, were observed in the left hemisphere with respect to normal brain. Previous studies have documented a subtle but consistent proinflammatory response in the contralateral hemisphere (Cowell et al., 2002) .
Immunohistochemistry assays enabled us to determine the neuroanatomic and cell-specific localization C3 and C9. Faint C3 and C9 immunoreactivity was consistently present in the extracellular matrix of the normal P7-P8 cortex (data not shown) and the left hemisphere of brains from animals 8 hr after HI (Fig.  2 A-D) . This distribution of diffuse C3 and C9 immunoreactivity was absent in normal adult rat brain (data not shown). In contrast, after HI, C3 and C9 were concentrated on cell bodies within injured areas. C3 and C9 were invariably localized to the same regions in each brain, but the time course of complement depo-sition varied among regions. The first regions in which complement deposition was observed included the medial habenula, dentate gyrus, thalamus, and CA1 region of the hippocampus (8 -48 hr). Changes were discerned later in the cortex and striatum (16 -48 hr), and immunoreactivity peaked in the CA3 region of the hippocampus between 48 and 72 hr. The specificity of C3 and C9 immunostaining was confirmed by the concurrent evaluation of negative control sections. In sections from normal brains, there was no immunostaining in negative controls. In sections from HI brains, there was typically light, diffuse, nonspecific immunostaining in the lesion territory.
At 8 hr after HI, a pronounced change in nuclear morphology was seen throughout the ipsilateral hemisphere in sections counterstained with cresyl violet (Fig. 2 , compare A-D and E-H ). Although nuclei in the left hemisphere were lightly stained, large, and ovoid, nuclei in the right hemisphere were intensely stained, condensed, and fragmented. C3 and C9 immunoreactivity was concentrated on ipsilateral cerebral endothelium, especially throughout the cortex (Fig. 2 E, G) ; we could not distinguish luminal versus abluminal sites of complement deposition. C3 and C9 immunoreactivity was sometimes detected on cell bodies (Fig. 2 E, G, arrowheads) . At 16 hr (data not shown) and 24 hr, C3 and C9 immunostaining was observed on cells throughout the right cortex and hippocampus (Fig. 2 I-L) as well as the habenula, striatum, and thalamus (data not shown). Complement immunoreactivity was detected on neuronal cell bodies and processes (Fig. 2 M-P) . By 72 hr, immunoreactivity declined in most regions (Fig. 2Q,S) . Intense immunostaining remained only on pyramidal cells within the hippocampal CA3 subfield (Fig. 2 R, T ) , on scattered cells with the morphology of phagocytic microglia (data not shown), and on cells in the left cortex where delayed cell death occurs (Cowell et al., 2002) . At 120 hr after HI, C3 and C9 immunostaining declined further, and only a few faintly immunoreactive cells were seen (data not shown).
To determine the identity of C3-and C9-immunoreactive cells, we used triple-labeling immunofluorescence and confocal microscopy. C3 and C9 were localized to ipsilateral endothelium 8 and 16 hr after HI (data not shown) and injured neurons throughout the ipsilateral hemisphere from 8 -72 hr after HI. Figure 3 highlights the cell specificity of complement deposition 24 hr after HI. An antibody raised against the neuronal protein NeuN was used to identify neurons; NeuN immunohistochemistry readily identifies areas of acute neuronal damage in this model (Cowell et al., 2002) . In comparison with the normal NeuN-positive neurons in the left cortex (Fig. 3A) , NeuNpositive neurons in the right cortex were smaller and sparsely distributed (Fig. 3D) . In the left cortex, light C3 immunoreactivity was detectable in the extracellular matrix (Fig. 3B) . In the right cortex, intense C3 immunoreactivity was located in areas of damaged neurons (Fig. 3E) . C3 was concentrated on small injured neurons and absent from the normal-appearing neurons in the vicinity ( Fig. 3D, box; 3G ). Numerous cells in the right hemisphere were also immunoreactive for the activated fragment of caspase 3 (Fig. 3F ) , indicating that these cells were dying by apoptosis, as reported previously in this model (Han et al., 2000) . C3 often colocalized with activated caspase 3 ( Fig. 3F, box; 3H , bright purple).
The distribution of C9 immunoreactivity was similar to that of C3. There was faint C9 immunostaining in the extracellular matrix of the left cortex (Fig. 3J ) but in the right cortex, C9 was concentrated on cells throughout the injured area (Fig. 3M ). When visualized with the nuclear counterstain DAPI, the nuclei of C9-negative cells in the left cortex were large and ovoid (Fig.  3 K, O) ; in contrast, the nuclei of injured C9-positive cells on the right side were small and fragmented (Fig. 3 N, P) . The concentration of C9 on injured cells confirmed that the increases in C9 observed by Western blotting were attributable to, at least in part, the formation of MAC on neurons. Triple labeling with NeuN, C3, and C9 antibodies indicated that C3 and C9 were deposited on the same injured cells (data not shown).
To investigate the contribution of systemically derived C3 to complement deposition and injury, we administered CVF 24 hr before HI lesioning to deplete systemic C3 and evaluated C3 and C9 deposition (at 24 hr) and tissue injury (at 5 d). C3 Western blot assays of serum samples from normal animals demonstrated that 24 -48 hr after CVF injection, ␣C3 (120 kDa) was eliminated (Fig. 4 A, B) ; C3 content began to recover at approximately P12. This CVF injection protocol also eliminated serum hemolytic activity within 24 hr [CH 50 Ϯ SEM; PBS (n ϭ 4): 0.082 Ϯ 0.01; Analysis of C3 content in brain homogenates by Western blot demonstrated that CVF administration on P6 resulted in a substantial reduction in normal brain C3 content by P7 that lasted until P12 (Fig. 4C,D) . In comparison with normal P7 brain (Fig.  4 E) , C3 immunostaining in the brains of CVF-treated animals was markedly diminished (Fig. 4 F) . CVF had no effect on serum or brain C9 (data not shown).
On the basis of the knowledge that complement activation can amplify inflammation, we hypothesized that systemic complement depletion would attenuate HI injury. However, given that the mode of action of CVF involves intravascular complement activation, we also recognized the possibility that CVF could augment ischemia-induced inflammation. Therefore, we evaluated the impact of CVF pretreatment using lesioning protocols that would enable us to discern both exacerbation and attenuation of injury. In preliminary experiments, CVF was administered on P6, animals underwent 1 hr of HI on P7, and tissue injury was evaluated on P12 (n ϭ 16 per group); there was minimal tissue damage in both groups (data not shown). In the next group of experiments, after P6 PBS or CVF administration, animals underwent 1.5 hr HI. Comparison of derived lesion volume and percentage of damage values (Table 1) indicated that overall injury was reduced in the CVFtreated group (n ϭ 16 -17 per group; p Ͻ 0.02; two-way ANOVA; region ϫ group). However, there was substantial variation in the extent of damage in CVF-treated animals, and in 4 of 16 CVF-treated animals, the extent of damage was greater than the group mean for PBS-treated animals.
To elucidate the mechanism of CVFmediated neuroprotection, we evaluated the influence of CVF administration on tissue complement activation by Western blot (Fig. 5) and deposition by immunohistochemistry (Fig. 6 ) at 24 hr after HI. CVF pretreatment reduced the amount of iC3b accumulation in the brain after injury (Fig. 5A) Note that the magnitude of iC3b accumulation in these samples was less than that observed for more severely lesioned brains (2 hr HI) (Fig. 1) .
C3 and C9 immunohistochemistry assays of PBS-HI and CVF-HI brains confirmed these findings. There was substantial C3 deposition in PBS-HI brains 24 hr after lesioning (compared with C3 in normal P8 brain) (Fig. 6 A, C) and, in CVF-HI brains, the intensity of C3 immunoreactivity in the right hemisphere was reduced in comparison with PBS-HI animals (Fig.  6 D-F ). Yet, there was a subtle increase in C3 immunoreactivity in the lesion territory compared with normal brain (Fig. 6 , compare D and B), and comparison with negative control sections confirmed that this immunoreactivity was specific. In contrast, C9 deposition was similar in PBS-HI and CVF-HI tissue (Fig.  6G,H ) . Corresponding immunofluorescence assays analyzed with confocal microscopy confirmed that faint C3 immunoreactivity colocalized with C9 on condensed NeuN-positive neurons (data not shown). It is important to note that for all complementdepleted animals that underwent HI lesioning and were killed on P8, serum C3 content was evaluated by Western blot analysis to confirm that C3 was depleted at the time of the killing and HI did not induce the systemic production of native C3 (data not shown).
Because C3 deposition was still observed in complementdepleted animals, we evaluated potential sources of C3 in the CVF-HI brains. Figure 6 , I-K, shows examples of several C3-immunoreactive cell types. In large round cells in the vicinity of dying neurons, C3 immunostaining was concentrated adjacent to the cell nucleus (juxtanuclear), suggestive of localization within the Golgi apparatus. These cells had the morphology of activated microglia and often exhibited cytoplasmic staining as well ( 6 I); C3 colocalized with the monocyte-microglia marker Isolectin (data not shown). Other C3-immunoreactive cell types included endothelium (Fig. 6 J) , ependyma (Fig. 6 K) , and choroid plexus (data not shown).
Discussion
Our results demonstrate that neonatal HI brain injury activates the complement cascade, complement components are deposited on endothelial cells and dying neurons, and CVF administration reduces infarct size. Our study also illustrates the complexities and limitations inherent in using CVF treatment to delineate the role of complement activation in cerebral ischemiareperfusion injury. Despite depletion of C3 in serum and brain by CVF administration, there was evidence of residual HI-induced complement deposition in lesioned brain, which was likely attributable to local C3 production. In addition, although there were robust overall differences in lesion severity between PBS and CVF-treated animals, there was substantial variation in the extent of neuroprotection conferred by treatment.
We confirmed complement activation in injured brain tissue using both Western blot assays to detect and quantify the accumulation of iC3b and C9 and immunohistochemistry to localize complement components to injured cells. Initial Western blot assays of C3 in neonatal brain were unsuccessful. Generation of samples markedly enriched in activated complement by intracerebral injection of Zymosan enabled us to develop an immunoprecipitation protocol and optimize immunoblot assays of C3, in which native and inactivated C3 fragments could be distinguished. Because all samples were obtained from animals perfused with saline before tissue collection, systemic circulation sources of iC3b were minimized. In general, there was concordance between results of tissue homogenate and immunocytochemistry assays of complement in HI brain. To the best of our knowledge, this is the first report confirming the deposition of inactivated complement components in brain tissue using Western blot analysis.
With immunohistochemistry, endothelial localization of C3 and C9 immunoreactivity was evident as early as 8 hr after HI. The contribution of the endothelium to the pathophysiology of HI injury in this neonatal stroke model is not well understood. Indirect evidence implicates endothelial mechanisms in the inflammatory response to ischemic brain injury. For example, in a recent study of the chemokine macrophage inflammatory protein (MIP)-1␣ in this model, the earliest HI-induced increases in MIP-1␣ expression were in monocytes within and closely associated with capillaries in the lesion territory 8 hr after HI (Cowell et al., 2002) , coinciding with the time point at which endothelial complement deposition was detected. Products of injuryinduced complement activation, such as C5a and iC3b, may mediate chemokine production by binding to their respective receptors (C5aR or CR3) on monocytes-microglia. C5aR is expressed by microglia (Barnum, 1995) , and C5a can enhance injuryinduced chemokine production in other injury models (Zhao et al., 2002) . Complement activation products can also disrupt endothelial integrity and signaling (Ward, 1991; Saadi and Platt, 1995) ; the inhibition of acute complement activation on endothelial integrity and chemokine production may have contributed to the neuroprotective effects of CVF.
C3 and C9 immunoreactivity was consistently detected by 16 hr after HI on injured neurons. Confocal microscopy analysis demonstrated complement deposition on apoptotic neurons (on the basis of their morphology and activated caspase-3 expression) in the lesion territory. Both exposure of phosphatidylserine on (Gewurz et al., 1993; Test and Mitsuyoshi, 1997; Mevorach et al., 1998) . Therefore, it is likely that in the acutely injured neonatal brain, neuronal apoptosis may serve as a local stimulus for complement activation. Although neuronal morphological changes indicative of injury (e.g., nuclear shrinkage) generally preceded complement deposition, local complement activation could exacerbate ischemic injury by multiple mechanisms, including recruitment of inflammatory cells, disruption of the blood-brain barrier, and amplification of local tissue damage via MAC formation and release of intracellular contents. In this regard, it is intriguing to consider results of a recent study in adult rats (Xiong et al., 2003) , which demonstrated that the sequential infusion of individual proteins of the membrane attack complex (C5b, C6, C7, C8, and C9) into the hippocampus induced seizures and cytotoxicity.
To determine whether complement activation influences HI lesion severity, systemic complement (C3 and C5) was depleted by administration of CVF 24 hr before HI, and the extent of tissue injury was assessed morphometrically 5 d later. Recently, investigators reported that CVF does not reduce HI brain injury in P7 (Imm et al., 2002) or P21 (Lassiter et al., 2001) rats. In those studies, outcome was analyzed 1-3 d after lesioning, time points at which the extent of tissue damage may be more difficult to evaluate in this neonatal stroke model. The extent of tissue damage and atrophy can be readily quantified at 5 d after lesioning (Liu et al., 1996) , and the longer recovery period incorporated in this study may have facilitated identification of attenuation of injury. CVF initially depletes systemic complement by activating the complement cascade, and this process can transiently elicit proinflammatory signaling (Candinas et al., 1996; Cowell et al., 2001) . We speculate that with a longer recovery period, the impact of this potential confounding factor was less pronounced. Note that a recent preliminary report (Ten et al., 2003) using genetically modified animals lacking the complement component C1q provides additional evidence that complement activation contributes to neonatal HI brain injury. In comparison with wild-type controls, P7 mice lacking C1q were resistant to HI brain injury.
To investigate the mechanisms contributing to CVFmediated neuroprotection, we evaluated the impact of CVF on complement activation and deposition in the brain. CVF administration markedly reduced injury-induced iC3b accumulation in tissue homogenates, indicating that the systemic circulation is a major source of C3 in the acutely injured brain. Yet, there was residual C3 immunoreactivity detected within several cell types in the lesion territory of CVF-treated HI animals. Of particular interest, microglia displayed immunoreactivity for C3 in a pattern that suggested production within the Golgi apparatus. Microglia may have generated sufficient amounts of C3 to initiate MAC formation, accounting for persistent injury-induced C9 deposition in CVF-treated animals. The observation of CVFinduced neuroprotection, despite C9 accumulation similar to that of controls, suggests that the neuroprotective effects of CVF may be mediated by a reduction in iC3b deposition or downstream activation products, rather than a reduction in MAC formation.
The findings of C3-immunoreactive microglia are congruent with results of previous studies in which mRNA transcripts encoding complement proteins were localized to microglia in animal models of transient global ischemia (Schafer et al., 2000) and cortical contusion (Bellander et al., 1996) . Microglia have been implicated as a source of pathogenically important complement . CVF depletes native C3 in serum and brain. Normal P6 rats received intraperitoneal injections of vehicle (PBS) or CVF (500 g/kg), and serum and brain samples were collected for C3 Western blot analysis (on P7, P8, and P12; n ϭ 3 per group) or immunohistochemistry (on P7). A, Comparison of serum C3 in samples from PBS and CVF-injected animals demonstrates that ␣C3 (120 kDa; target of C3 convertase-CVF) is absent in CVF-treated animals on P7 and P8, and a faint ␣C3 band is detected on P12. B, Quantitative analysis of serum ␣C3. Serum samples from P7 (P6 PBS) and P7, P8, and P12 (P6 CVF) animals (n ϭ 3 per group) were included on the same gel and immunoblotted for C3. Band intensity expressed in arbitrary OD units Ϯ SEM ␣C3 is absent in P7 and P8 serum. C, C3 immunoprecipitation and Western blot of brain samples reveals that P6 CVF reduces ␣C3 in P7, P8, and P12 brain. D, Quantitative analysis of ␣C3 in brain. C3 was immunoprecipitated from P7 (P6 PBS) and P7, P8, and P12 (P6 CVF) brain, and samples (n ϭ 3 per group) were assayed on the same gel. Band intensity is expressed in arbitrary OD units Ϯ SEM. P6 CVF eliminates C3 from P7, P8, and P12 brain. E, F, Animals were injected with PBS ( E) or CVF ( F) on P6 and perfused on P7 for C3 immunohistochemistry. Representative sections at the level of the hippocampus revealed that in normal P7 brain, C3 immunoreactivity is distributed throughout the cortex, hippocampus, thalamus, and white matter; P6 CVF administration markedly reduces C3 immunoreactivity throughout the P7 brain. Scale bar: E, F, 1 mm. production in several neurodegenerative disorders, including Alzheimer's disease (McGeer et al., 2000) and Huntington disease (Singhrao et al., 1999) . Potential regulators of microglial C3 production in HI brain include C1q (Bajtay et al., 2000) and cytokines, such as interleukin-1␣ and -1␤, tumor necrosis factor-␣, and TGF-␤ (Hogasen et al., 1995; Mrak et al., 1995; Veerhuis et al., 1999) . Other CNS cells that may produce C3 . Systemic complement depletion does not eliminate complement deposition in the injured brain. A, B, Normal P6 animals were injected with either PBS or CVF and were perfused on P8. Representative sections at the level of the anterior hippocampus in normal P8 brain demonstrate C3 immunoreactivity throughout the cortex and concentrated along the ependymal cell layer in the hippocampus and thalamus ( A). CVF treatment on P6 reduces C3 immunoreactivity throughout the P8 brain ( B). C-I, After PBS or CVF injection on P6, P7 rats underwent right carotid ligation followed by 1.5 hr hypoxia and were perfused on P8. Representative brain sections from PBS-HI ( C) and CVF-HI ( D) animals show that the intensity of injury-induced C3 immunoreactivity is reduced in CVF-HI animals in comparison with PBS-HI animals. When the right cortex of each animal is viewed at higher magnification, it is evident that C3 immunoreactivity is concentrated on cell bodies and within the extracellular matrix in the PBS-HI animal (E, C, box) but is greatly reduced overall in the CVF-HI animal (F, D, box) . Although reduced, C3 immunoreactivity is not completely eliminated in the CVF-HI animals. Serial sections were processed for C9 immunohistochemistry; the intensity of C9 immunoreactivity did not differ significantly between PBS-HI ( G) and CVF-HI ( H ) animals. In the CVF-HI brain, cell types other than neurons were C3 immunoreactive; cells with microglial morphology displayed C3 immunoreactivity throughout the cytoplasm and concentrated adjacent to the nucleus ( I ) (confirmed with cresyl violet counterstain; data not shown). Other C3-immunoreactive cells in the right hemisphere of the CVF-HI brain include endothelium ( J) and ependyma ( K). include ependyma, choroid plexus, endothelium, and astrocytes (Barnum et al., 1996; Nadeau and Rivest, 2001) . In preliminary reverse transcriptase-PCR assays, we found increased C3 mRNA in the HI hemisphere as early as 16 hr after HI (R.M.C., unpublished observations). Gasque et al. (2000) postulated that methods that modulate the local synthesis of complement regulators (i.e., glial-or neuron-targeted gene therapy) may effectively inhibit deleterious complement activation in the brain. In fact, astrocyte-targeted expression of the complement inhibitor sCrry inhibits demyelination in a rat model of multiple sclerosis (Davoust et al., 1999) . Although no C3 immunoreactivity was detected in the adult brain, C3 was consistently identified in P7 brain by both immunohistochemistry and Western blot analysis. Systemic CVF administration substantially depleted C3 from the P7 brain, supporting the idea that brain C3 is primarily derived from the systemic circulation. This interpretation is strengthened by the observation that, in comparison to the serum from CVF-depleted animals (Fig. 5A) , the brain samples from these animals have little ␤C3 (Fig. 5C) . Thus, the presence of native C3 molecule in the CNS was reduced by CVF administration. Native C3 is a large molecule (ϳ185 kDa) and may not passively diffuse across the intact blood-brain barrier (BBB). However, numerous transport mechanisms unique to the neonatal BBB (Saunders et al., 1999) could be responsible for shuttling C3 from the circulation into the CNS. In addition, microglia in younger rats (P3) are intensely immunoreactive for C3 (R.M.C., unpublished observation), suggesting that these cells may be an additional source of C3 in the developing brain. Both the systemic circulation and intrinsic CNS cells may provide the developing brain with complement for innate defense against invading organisms (Gasque et al., 2000) and for rapid responses to injury.
There is growing recognition that inflammatory mediators can exert beneficial as well as detrimental effects during the recovery period after acute brain injury (Mason et al., 2001) . Although a preponderance of data suggests that complement activation exacerbates neurodegeneration, C5a may also exert neuroprotective effects (Mukherjee and Pasinetti, 2001) . In addition, because iC3b increases the efficiency of phagocytosis by binding to complement receptor CR3 (Mac-1; CD11b) (Takizawa et al., 1996) , complement inhibition could reduce removal of cell debris, thereby disrupting intrinsic repair mechanisms. Future studies will focus on delineating the sites and times at which complement inhibition can most effectively minimize amplification of tissue damage and enhance recovery after neonatal HI brain injury.
